EP3829714A1 - Composition nutraceutique orale destinée à être utilisée dans le traitement du syndrome métabolique - Google Patents
Composition nutraceutique orale destinée à être utilisée dans le traitement du syndrome métaboliqueInfo
- Publication number
- EP3829714A1 EP3829714A1 EP19758812.2A EP19758812A EP3829714A1 EP 3829714 A1 EP3829714 A1 EP 3829714A1 EP 19758812 A EP19758812 A EP 19758812A EP 3829714 A1 EP3829714 A1 EP 3829714A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- oral composition
- composition according
- extract
- content
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 17
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 17
- 238000011282 treatment Methods 0.000 title claims abstract description 14
- 239000002417 nutraceutical Substances 0.000 title abstract description 16
- 235000021436 nutraceutical agent Nutrition 0.000 title abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 30
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims abstract description 18
- 235000003198 Cynara Nutrition 0.000 claims abstract description 17
- 241000208947 Cynara Species 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 11
- 150000007513 acids Chemical class 0.000 claims abstract description 11
- 244000161488 Berberis lycium Species 0.000 claims abstract description 9
- 235000008130 Berberis lycium Nutrition 0.000 claims abstract description 9
- 238000009472 formulation Methods 0.000 claims abstract description 8
- 235000020744 piper nigrum extract Nutrition 0.000 claims abstract description 7
- 229940075559 piperine Drugs 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 claims description 12
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 claims description 12
- 235000019100 piperine Nutrition 0.000 claims description 12
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 6
- 229920000053 polysorbate 80 Polymers 0.000 claims description 6
- 229940068968 polysorbate 80 Drugs 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 150000001844 chromium Chemical class 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 244000203593 Piper nigrum Species 0.000 claims description 4
- 235000008184 Piper nigrum Nutrition 0.000 claims description 4
- 229940124532 absorption promoter Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 235000019156 vitamin B Nutrition 0.000 claims description 4
- 239000011720 vitamin B Substances 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- 238000009736 wetting Methods 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 229940046374 chromium picolinate Drugs 0.000 claims description 2
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical group [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000006194 liquid suspension Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- -1 sorbitan ester Chemical class 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 8
- 229940093265 berberine Drugs 0.000 description 8
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 208000024172 Cardiovascular disease Diseases 0.000 description 7
- 244000019459 Cynara cardunculus Species 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 235000019106 Cynara scolymus Nutrition 0.000 description 5
- 238000008214 LDL Cholesterol Methods 0.000 description 5
- 235000016520 artichoke thistle Nutrition 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 4
- 240000000724 Berberis vulgaris Species 0.000 description 4
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000035604 cholesterolaemia Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009862 primary prevention Effects 0.000 description 3
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 244000298479 Cichorium intybus Species 0.000 description 2
- 235000007542 Cichorium intybus Nutrition 0.000 description 2
- 235000003200 Cynara cardunculus Nutrition 0.000 description 2
- 235000005921 Cynara humilis Nutrition 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 2
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 2
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 235000007189 Oryza longistaminata Nutrition 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241001093575 Alma Species 0.000 description 1
- 244000003027 Bergamotto Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 244000272323 Cirsium lanceolatum Species 0.000 description 1
- 235000010856 Cirsium lanceolatum Nutrition 0.000 description 1
- 241000723377 Coffea Species 0.000 description 1
- 235000020881 DASH diet Nutrition 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241001490312 Lithops pseudotruncatella Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 235000001412 Mediterranean diet Nutrition 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 244000113306 Monascus purpureus Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000042032 Petrocephalus catostoma Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 240000001085 Trapa natans Species 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000078534 Vaccinium myrtillus Species 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 235000013614 black pepper Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000003494 hepatotrophic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 150000003244 quercetin derivatives Chemical class 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Definitions
- the present invention relates to a composition, in particular a nutraceutical formulation for the treatment of the metabolic syndrome.
- berberine chloride an alkaloid extracted from plants of the genus Berberis, characterized by the following formula, is certainly worth of consideration
- BERC pharmacological synergies in terms of reduction of plasma cholesterol fractions, in particular LDL and fasting glycaemia and to favour the restoration of a trophic state of the hepatic parenchyma, reducing steatosis and normalizing the secretion of intracellular enzymes such as GOT and GPT, indicators of hepatocytic cell damage during exotoxic liver diseases.
- the black pepper pipeline acts as an inhibitor of the metabolization of pharmacological and nutraceutical active ingredients, in particular by inhibiting the enzyme UDP-glucuronyl transferase, responsible for enterocytic and hepatic glucuronidation
- PS 80 polyoxyethylene sorbitan ester with oleic acid
- WO 2014/044744 Al describes compositions for the treatment of the metabolic syndrome containing, as essential ingredients, the Cynara scolimus extract with a content of 30-45% in caffeoylquinic acid, extracts of Coffea spp with a content of caffeoylquinic acids ranging from 40 to 80% by weight and finally an Olea europaea extract.
- JP 2013 237656 A reports that pipeline is used as an anti-dyslipidaemic agent, as it prevents the differentiation and maturation of cells in adipocytes.
- US 2016/106793 Al describes a composition containing a combination of at least 3 extracts (including Cynara Scolimus , Chrysanttellum indicum and Vaccinium myrtillus) together with pipeline for the treatment of metabolic disorders.
- EP 2 810 941 Al describes piperine derivatives having anti-dyslipidaemic activity, PANAHI YUNES ET AL in "Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: Results of a randomized controlled t", COMPLEMENTARY THERAPIES IN MEDICINE, vol. 22, no. 5, pages 851-857, XP029080004,ISSN: 0965-2299, DOI:
- NOMIKOS ET Al in "Boiled wild artichoke reduces postprandial glycemic and insulinemic responses in normal subjects but has no effect on metabolic syndrome patients", NUTRITION RESEARCH, ELSEVIER INC, XX, vol. 27, no. 12, 26 November 2007 (2007-11-26), pages 741-749, XP022361961, ISSN: 0271-5317, DOI: 10.1016/J.NUTRES.2007.09 .009 reports the activity of Cynara cardiunculus extracts (thistle or wild artichoke) in reducing blood glucose and postprandial insulin only on healthy subjects but not on individuals with metabolic syndrome.
- JURGONSKI ADAM ET AL in "Caffeoylquinic acid-rich extract from chicory seeds improves glycaemia, atherogenic index, and antioxidant status in rats", NUTRI, vol. 28, no. 3, 1 March 2012 (2012-03-01), pages 300-306,
- XP009166712, ISSN: 1873-1244, DOI: 10.1016/J.NUT.2011.06.010 [retrieved on 2011-10-19] report that chicory extracts rich in caffeoylquinic acids are effective in the treatment of metabolic syndrome together with rutin, a quercetin derivative.
- WO 2018/189672 Al describes the association of the Cynara cordiunculus extract that, as noted above, is the common thistle, with an extract of another plant, Citrus aurantium bergamia, in the treatment of hepatic steatosis and in the treatment of dyslipidaemia.
- the oral composition that is the object of the present invention and comprises Berberis aristata extract with a minimum titre of 50% in BERC, Cynara scolimus extract with a minimum title of 2.5% in caffeoylquinic acids, dispersed in a suspension of polysorbate 80 and Piper Nigrum extract with a minimum titre of 80% in piperine, shows a high efficacy, clinically documented, in normalizing the lipidic, glucidic and hepatic profile in patients with moderate hypercholesterolemia and compatible with the initial clinical signs of metabolic syndrome.
- the object of the present invention is an oral composition comprising
- the association of polysorbate 80 - piperine has not been described yet, at least in the form of intimate mixing of the second in the first, as foreseen in the process to prepare the aforementioned formulation in order to obtain an enteric absorption promoter capable of simultaneously improving the diffusion of the active ingredient through the UWP and the inhibition of UDP-glucuronyl transferase in the enterocyte.
- the further object of the present invention namely the industrial method for the preparation of the aforementioned oral composition, preferably in the form of a gastro-resistant tablet, comprises in particular the following steps:
- step b) wetting the powder coming from step b) with the liquid suspension of step a);
- step c) merging the obtained wet powder coming from step c) with possible excipients such as calcium phosphate, microcrystalline cellulose and magnesium stearate in order to obtain a dry, smooth and compressible powder;
- step d compressing the powder obtained in step d;
- This process is characterized by the wetting of the powder mixture composed of Berberis aristata extract and Cynara scolimus extract titrated in caffeoylquinic acids into the suspension of the polyoxyethylenate sorbitan ester and Piperine, prepared in step a.
- the intimate mixing of the two active principles with the aforementioned absorption promoters achieved in the step c of the process of the invention allows obtaining a final powder, which is subsequently compressed and coated with a film that ensures the overcoming of the gastric transit and the subsequent disaggregation in the first enteric tract (3 hours), considerably increases the effectiveness of the absorption promotion system thus favouring an increased clinical response compared to the mere association of the active ingredients.
- Cynara scolimus titrated in caffeoylquinic acids is responsible for a cholesterol-lowering effect synergistic to that of BERC and of a hepato-trophic and detoxifying effect, responsible for the normalization of the plasma enzyme profile (GOT, GPT).
- the definition "comprising" before a list of components, as in the case of the oral composition object of the invention or of steps as in the process, further object of the invention, does not exclude the presence of further components or steps besides those listed.
- the Berberis aristata extract preferably has a titre of 98% in berberine chloride.
- the Berberis aristata is present in the formulations object of the invention in such a content that the berberine chloride is present in a variable amount between 250 and 500 mg.
- the Cynara scolimus extract is present in amounts such as to have a caffeoylquinic acid content of between 0.5 and 5 mg.
- Polysorbate 80 also known as PS80, is preferably used as sorbitan polyoxyethylenate ester.
- the sorbitan polyoxyethylenate ester content can vary from a minimum of 1% to a maximum of 10% by weight of the weight of the oral composition.
- the Piper nigrum extract has a piperine titre between 95 and 98%.
- the Piper nigrum is present in such amounts that the piperine content varies between a minimum of 0.1% by weight to a maximum of 2% of the total weight of said composition.
- Oral compositions may also contain as an active ingredient a vitamin belonging to B vitamins and a pharmaceutically acceptable chromium salt to further promote the normalization of glycaemia.
- the oral composition object of the present invention comprises picolinate chromium as pharmaceutically acceptable chromium salt, and as B vitamins, the oral composition object of the invention contains vitamin Bl and folic acid to assist the hypoglycaemic effect.
- the oral composition according to the present invention comprises chromium picolinate, vitamin Bl and folic acid.
- the oral compositions object of the present invention can be in the form of granulates or gastro-resistant tablets, even if as mentioned above, the latter are particularly preferred.
- compositions according to the present invention are preferably in the form of nutraceutical formulations and are in particular suitable for the treatment of the metabolic syndrome.
- a nutraceutical is, in its original definition, a food, or part of a food with proven beneficial and protective effects on both the physical and psychological health of the individual, according to what reported in the review entitled NUTRACEUTICA: DEFINIZIONE, REGOL AMENT AZIONE E APPLICAZIONI by A. Pirillo and A.L. Catapano and published in Giornale Italiano di Farmacoeconomia e Farmacoutilizzaée 2014; 6 (4): 23-30.
- the possible excipients are selected from at least one of the following: calcium phosphate, microcrystalline cellulose and magnesium stearate in order to obtain a dry, smooth and compressible powder.
- an oral composition according to the present invention in the form of a gastro-resistant tablet is reported below for illustrative purposes.
- cardiovascular diseases Despite the progress in scientific knowledge about the prevention of cardiovascular diseases, they still represent the most frequent cause of death in the world today, causing the death of about 4 million people every year in Europe alone. In particular, cardiovascular diseases related to atherosclerosis are responsible for 42% of deaths in women and 38% in men under 75 [12]
- cardiovascular diseases Several known risk factors contribute to the development of cardiovascular diseases; classically they are divided into factors that can be modified with lifestyle changes or a pharmacological treatment (e.g. hypercholesterolemia, hypertension, smoking, diabetes mellitus) and non-modifiable factors (age, male sex, familiarity).
- pharmacological treatment e.g. hypercholesterolemia, hypertension, smoking, diabetes mellitus
- non-modifiable factors e.g. hypercholesterolemia, hypertension, smoking, diabetes mellitus
- non-modifiable factors e.g. hypercholesterolemia, hypertension, smoking, diabetes mellitus
- non-modifiable factors e.g. hypertension, smoking, diabetes mellitus
- high concentrations of LDL cholesterol represent one of the main independent cardiovascular risk factors [13]
- the lipid-lowering nutraceuticals described in the literature are numerous and their use is supported by different levels of scientific evidence and efficacy [15]
- the single most effective (and even best-selling) nutraceutical is fermented red rice extract, whose active ingredient is monacolin K, a substance produced by fermentation of common rice by the fungus Monascus purpureus.
- Monacolin K is very effective, as it has the same chemical structure as synthetic lovastatin [16]
- this analogy has its disadvantages, because it is associated with the same side effects of statins (although attenuated by the dosage limitations provided for by the law) and the same risk of drug interactions, for which some European Union states are proposing employment restrictions.
- the aim of this study was the evaluation of the short-term metabolic effect of the combination of other cholesterol-lowering nutraceuticals with a different action from statins such as dry extracts of artichoke and berberis in patients suffering from moderate hypercholesterolemia in primary prevention for cardiovascular diseases.
- Example 1 placebo (indistinguishable in shape and volume), for a duration of 8 weeks, in association with a standardized Mediterranean diet.
- the combined nutraceutical significantly reduced levels of total cholesterol, LDL (calculated and dosed) and non-HDL cholesterol, triglycerides, basal glycaemia, GOT and GPT compared to baseline, while cholesterolaemia HDL has increased compared to baseline (Table 2).
- the values of total cholesterol, LDL (calculated and dosed) and non-HDL cholesterol decreased significantly even compared to placebo (Table 2).
- Table 1- Baseline clinical and laboratory values in the two treatment groups
- Li -Blatter X Nervi P, Seelig A. Detergents as intrinsic P-glycoprotein substrates and inhibitors. Biochim Biophys Acta. 2009 Oct;l788(lO):2335-44;
- EACPR Cardiovascular Prevention & Rehabilitation
- 2016 ESC/EAS Guidelines for the management of dyslipidaemias The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2016; 37:2999-3058
- Cicero AFG Red yeast rice, monacolin K, and pleiotropic effects. Recenti Prog Med. 20l8;l09(2): l54e-l57e.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102018000007746A IT201800007746A1 (it) | 2018-08-01 | 2018-08-01 | Composizione orale nutraceutica per uso nel trattamento della sindrome metabolica |
PCT/IB2019/056566 WO2020026186A1 (fr) | 2018-08-01 | 2019-08-01 | Composition nutraceutique orale destinée à être utilisée dans le traitement du syndrome métabolique |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3829714A1 true EP3829714A1 (fr) | 2021-06-09 |
Family
ID=63965880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19758812.2A Pending EP3829714A1 (fr) | 2018-08-01 | 2019-08-01 | Composition nutraceutique orale destinée à être utilisée dans le traitement du syndrome métabolique |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3829714A1 (fr) |
IT (1) | IT201800007746A1 (fr) |
WO (1) | WO2020026186A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT202100012890A1 (it) * | 2021-05-19 | 2022-11-19 | Carlo Sessa S P A | Miscela in polvere a base di estratto secco di Berberis Aristata e derivato della vitamina E |
IT202100028598A1 (it) * | 2021-11-10 | 2023-05-10 | Arm R&D Soc A Responsabilita Limitata Semplificata | Associazione di Oleuropeina, Berberina e Florizina per il trattamento e la prevenzione della sindrome metabolica |
WO2023156853A1 (fr) * | 2022-02-21 | 2023-08-24 | Omniactive Health Technologies Limited | Composition de berbéris pour la santé cognitive |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101186500B1 (ko) * | 2012-01-31 | 2012-09-27 | 연세대학교 산학협력단 | 신규한 피페린 유도체 및 그의 용도 |
JP5923381B2 (ja) * | 2012-05-17 | 2016-05-24 | 花王株式会社 | PPARγ活性抑制剤 |
ITMI20121570A1 (it) * | 2012-09-20 | 2014-03-21 | Indena Spa | Nuovi estratti di cynara scolimus, coffea spp. e olea europaea per il trattamento della sindrome metabolica |
FR3027228B1 (fr) * | 2014-10-20 | 2016-12-09 | Valbiotis | Composition comprenant un melange d'extraits vegetaux et utilisation pour agir sur le metabolisme glucidique et/ou lipidique |
IT201700040866A1 (it) * | 2017-04-12 | 2018-10-12 | Herbal E Antioxidant Derivatives Srl Ed In Forma Abbreviata H&Ad Srl | Estratti di cynara scolymus e citrus aurantium bergamia, loro combinazioni e formulazioni che li contengono |
-
2018
- 2018-08-01 IT IT102018000007746A patent/IT201800007746A1/it unknown
-
2019
- 2019-08-01 WO PCT/IB2019/056566 patent/WO2020026186A1/fr unknown
- 2019-08-01 EP EP19758812.2A patent/EP3829714A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
IT201800007746A1 (it) | 2020-02-01 |
WO2020026186A1 (fr) | 2020-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cicero et al. | Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: the available clinical data | |
Santini et al. | Nutraceuticals: A paradigm of proactive medicine | |
Hunter et al. | Functional foods and dietary supplements for the management of dyslipidaemia | |
Cicero et al. | Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents | |
Gonnelli et al. | Efficacy and tolerability of a nutraceutical combination (red yeast rice, policosanols, and berberine) in patients with low-moderate risk hypercholesterolemia: a double-blind, placebo-controlled study | |
US11975108B2 (en) | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation | |
WO2020026186A1 (fr) | Composition nutraceutique orale destinée à être utilisée dans le traitement du syndrome métabolique | |
US8895079B2 (en) | Combinations of botanical extracts for promoting cardiovascular health | |
Fatahian et al. | Promising anti-atherosclerotic effect of berberine: evidence from in vitro, in vivo, and clinical studies | |
JP2021512062A (ja) | ベルベリンを含む組成物 | |
ITUB20150541A1 (it) | Composizione comprendente sostanze e/o estratti naturali | |
Tahmasebi et al. | Randomised clinical trial of Berberis vulgaris root extract on glycemic and lipid parameters in type 2 diabetes mellitus patients | |
Cicero et al. | Handbook of nutraceuticals for clinical use | |
Al Jamal | Effect of rosemary (Rosmarinus officinalis) on lipid profiles and blood glucose in human diabetic patients (type-2) | |
Visioli et al. | Prevention and treatment of atherosclerosis: the use of nutraceuticals and functional foods | |
Chen et al. | The current trend and challenges of developing red yeast rice-based food supplements for hypercholesterolemia | |
Rami et al. | Efficacy of lactuca sativa in hyperlipidemia: a pilot study | |
Knaub et al. | Effect LDL-cholesterol lowering effect of hydroxytyrosol (HTEssence®): A randomized double-blind, placebo-controlled parallel study | |
Adi et al. | DOUBLE BLIND RANDOMIZED CONTROLLED STUDY ON THE EFFICACY OF ASPARAGUS RACEMOSUS MOTHER TINCTURE IN HYPERLIPIDEMIA | |
Chen et al. | Red mold dioscorea decreases blood pressure when administered alone or with amlodipine and is a potentially safe functional food in SHR and WKY rats | |
CN105246472B (zh) | 含有鸟氨酸和/或门冬氨酸的组合物及其应用 | |
TR201807019T4 (tr) | Kroni̇k böbrek hastaliğinda di̇sli̇pi̇demi̇ tedavi̇si̇nde kullanilmak üzere bi̇leşi̇mler. | |
Chen et al. | A Randomized, Double-Blind Clinical Study on Blood Pressure Reduction and Blood Lipid Profile Amelioration on Treatment with Ankascin 568 | |
Ferri et al. | USING NUTRACEUTICALS AND FUNCTIONAL FOODS TO MODULATE CHOLESTEROL CONCENTRATIONS | |
KR20170026241A (ko) | 경구용 복합제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210211 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240620 |
|
17Q | First examination report despatched |
Effective date: 20240626 |